Production of human parathyroid hormone from microorganisms

ABSTRACT

The invention provides recombinant plasmids containing in DNA sequences coding for human preproparathyroid hormone. The invention further provides microorganisms, for example E. coli, transformed by these plasmids. The invention also provides a plasmid for insertion into yeast and a transformed yeast in which the plasmid contains DNA coding for parathyroid hormone. Parathyroid hormone is then secreted by the transformed yeast. Further the invention provides alternate polypeptides having parathyroid hormone activity, including PTH analogs, fragments and extensions, and provides alternate leader sequences and secretion signal sequences which can be used in the present invention. Finally, there are provided methods for purification of the secreted PTH hormone and/or derivatives.

This application is a divisional application of Ser. No. 08/340,664filed Nov. 16, 1994 which is a divisional application of Ser. No.08/087,471 filed Jul. 2, 1993, now U.S. Pat. No. 5,420,242, issued May30, 1995 which is a continuation of U.S. Ser. No. 07/821,478 filed Jan.15, 1992, now abandoned, which is a continuation of U.S. Ser. No.07/404,970, filed Sep. 8, 1989, now abandoned, which is acontinuation-in-part application of Ser. No. 07/393,851 filed Aug. 14,1989, now U.S. Pat. No. 5,010,010, which is a continuation of U.S. Ser.No. 06/921,684, filed Oct. 22, 1986, now abandoned.

FIELD OF THE INVENTION

This invention relates to genetically engineered microorganismscontaining DNA coding for human preproparathyroid hormone.

BACKGROUND OF THE INVENTION

A number of proteins and peptides that are normally synthesized bymammalian cells have proven to have medical, agricultural and industrialutility.

These proteins and peptides may be of different molecular size and havea number of different functions, for example, they may be enzymes,structural proteins, growth factors and hormones. In essence bothproteins and peptides are composed of linear sequences of amino acidswhich form secondary and tertiary structures that are necessary toconvey the biological activity. Human parathyroid hormone has arelatively small molecular weight, which has made it possible tosynthesize the peptide chemically by the sequential addition of aminoacids. Thus, parathyroid hormone is commercially available, but in verysmall quantities at high cost. As a result, there is no humanparathyroid hormone available at a reasonable price to supply the manypotential medical, agricultural and industrial applications.

During the past ten years, microbiological techniques employingrecombinant DNA have made it possible to use microorganisms for theproduction of species-different peptides. The microorganism is capableof rapid and abundant growth and can be made to synthesize the foreignproduct in the same manner as bacterial peptides. The utility andpotential of this molecular biological approach has already been provenby microbiological production of a number of human proteins that are nowavailable for medical and other uses.

Parathyroid hormone (PTH) is one of the most important regulators ofcalcium metabolism in mammals and is also related to several diseases inhumans, animals, e.g. milk fever, acute hypocalsemia and otherwisepathologically altered blood calcium levels. This hormone therefore willbe important as a part of diagnostic kits and will also have potentialas a therapeutic in human and veterinary medicine.

The first synthesis of DNA for human preproparathyroid hormone wasdescribed by Hendy, G. N., Kronenberg, H. M., Potts, Jr. J. T. and Rich,A. 78 Proc. Natl. Acad. Sci. 7365-7369 (1981). DNA complementary insequence to PTH mRNA was synthesized and made double stranded (Hendy etal. supra). This cDNA was cloned in pBR 322 DNA and E. coli 1776 wastransfected. Of the colonies with correct antibiotic resistance, 23 outof 200 clones were identified as containing specific human PTH cDNAinserts. However, none of the 23 human PTH clones contained the fulllength insert (Hendy et al., supra). Later Breyel, E., Morelle, G.,Auf'mkolk, B., Frank, R., Blocker, H. and Mayer, H., Third EuropeanCongress on Biotechnology, 10-14 September 1984, Vol. 3, 363-369described the presence of the human PTH gene in a fetal liver genomicDNA library constructed in the phage Charon 4A. A restriction enzymefragment of the PTH gene was recloned and transfected into E. coli.

However, the work of Breyel, supra, demonstrated that E. coli degradeshuman PTH. Thus, a microorganism which shows a stable production ofintact human parathyroid hormone has so far not been described.

Further, parathyroid hormone has never before been isolated from yeast.

SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide aplasmid containing DNA coding for human preproparathyroid hormone (hPTH)for insertion in Escherichia coli. It is another object of the presentinvention to provide a genetically engineered E. coli containing DNAcoding for human preproparathyroid hormone.

A further object of the present invention is to provide a plasmid forinsertion in yeast containing DNA coding for parathyroid hormone("PTH"), It is also an object of the present invention to provide atransformed yeast containing DNA coding for parathyroid hormoneincluding human parathyroid hormone, and from which transformed yeast,parathyroid hormone may be obtained.

Another object of the present invention is to provide new polymershaving parathyroid hormone activity including PTH fragments, extensionand analogs. Yet another object is to provide alternate leader sequencesand secretion signal sequences which can be used in the practice of thepresent invention.

A still further object of the invention is to provide downstream processtechnology for purification of intact PTH, as well as purification ofanalogs, fragments and extensions.

Other objects and advantages of the present invention will becomeapparent as the description thereof proceeds.

In satisfaction of the foregoing objects and advantages, there isprovided by the present invention a novel plasmid for insertion in E.coli, containing DNA coding for human preproparathyroid hormone. Theplasmid when inserted into E. coli functions to transform the E. colisuch that the E. coli then produces multiple copies of the plasmid andthus of the cDNA coding for human preproparathyroid hormone. The plasmidfor human insertion into E. coli of the present invention and thus thetransformed E. coli are distinguishable over prior art plasmids andmicroorganisms, for example as described in Hendy et al., supra, in thatthe plasmid of the present invention contains a double start codon atthe 5' end of the DNA coding for preproparathyroid hormone. The presenceof the double start codon may cause production microorganismstransformed with a plasmid containing the cDNA to producepreproparathyroid hormone at an increased rate and in an improved yieldover prior art transformed microorganisms.

There is further provided by the present invention a plasmid forinsertion into yeast containing DNA coding for parathyroid hormone. In apreferred embodiment, this plasmid is prepared by recloning the plasmidfor insertion in E. coli described above. Moreover, the inventionprovides a yeast transformed by said plasmid for insertion in yeast suchthat the yeast produces and secretes parathyroid hormone. Thus, theinvention provides a method by which parathyroid hormone may be isolatedfrom yeast culture medium. In a preferred embodiment, the transformedyeast is Saccharomyces cerevisiae. In another preferred embodiment, theparathyroid hormone is human parathyroid hormone.

By use of in vitro mutagenesis, the present invention also providessubstitution of one or more amino acids in human parathyroid hormone andpeptides having parathyroid hormone agonistic or antagonistic activity.Further, there are provided analogs, fragments, or extensions of theparathyroid hormone (collectively referred to as "derivatives") whichalso show agonistic or antagonistic activity. Examples of these peptideshave been produced as secretory products in yeast and in E. coli.

The present invention further provides different leader sequences andsecretion signal sequences that may be used for the production andsecretion of the PTH hormone and/or its derivatives. In at least oneinstance, an alternate leader sequence provides improved production ofthe desired hormone or derivative.

Additionally, the invention provides a downstream process technology forpurification of human parathyroid hormone and derivatives. The processinvolves a purification procedure for yeast or E. coli medium orperiplasmic solution, and consists principally of cation exchangechromatography followed by two steps of high pressure liquidchromatography. The final product is more than 95 percent pure and canbe submitted directly to N-terminal amino acid sequencing as well asamino acid composition determination.

Human parathyroid hormone (hPTH) is a key regulator of calciumhomeostasis. The hormone is produced as a 115 amino-acid prepro-peptide.Before secretion the prepro part is cleaved off, yielding the 84 aminoacid mature hormone. Through its action on target cells in bone andkidney tubuli, hPTH increases serum calcium and decreases serumphosphate, while opposite effects are found regarding urinary excretionof calcium and phosphate. At chronically high secretory rates of PTH(hyperparathyroidism) bone resorption supersedes formation. However,prolonged exposure to low/moderate doses of a biologically activePTH-fragment stimulates bone formation and has also been reported to beeffective in the treatment of osteoporosis by inducing an anabolicresponse in bone (Reeve et al. 1980 Br Med J 250, 1340-1344; Slovik etal. 1986 J Bone Min Ros 1, 577). So far studies on intact hPTH have beenhampered by the limited availability and the high price of the hormone.Hence a system for the efficient expression of hPTH in microorganismswould be very advantageous for the further progression of studies onhPTH and its role in bone biology and disease.

Poly (A)⁺ -selected RNA was isolated from human parathyroid adenomasimmediately after surgery. The RNA was size-fractionated, cDNA wasprepared and cloned into the PstI site of pBR322 by the GC-tailingmethod. The library was screened by using synthetic oligonucleotides.Sixty-six clones of a total of 34,000 were found to be positive for both5' and 3' PTH sequences. The correct identity of four of these cloneswas verified by DNA sequence analysis.

Employing the promoter and signal sequence of Staphyloccous aureousprotein A we have expressed hPTH in Escherichia coli as a secretorypeptide. Immunoreactive PTH was isolated both from growth medium andperiplasmic space. We obtained up to 10 mg/l hPTH as judged byreactivity in radioimmunoassay.

hPTH was expressed in Saccharomyces cerevisiae after fusing hPTH cDNA toan expression vector coding for the prepro-region of the yeast matingfactor α.

During the secretion process, the α-factor leader sequence is cleavedoff by an endopeptidase specific for a dibasic amino acid sequence andencoded by the KEX2 gene.

By hPTH-specific radioimmunoassay a significant amount of hPTHimmunoreactive material was detected in the growth medium, correspondingto about 1 mg hPTH pr 1 medium, of the yeast strain FL200 transformedwith fusion plasmid pαLXPTH. No immunoreactive hPTH was secreted fromcells transformed with the vector pαLX.

Parallel cultures of the yeast strain FL200 transformed with one of thethree expression plasmids pUCXPTH, pαUXPTH-1 and pαLXPTH with copynumbers near unity, normal high (-30) and very high (>50) respectivelywere grown and both growth medium, a periplasmic fraction and anintracellular soluble fraction were assayed for hPTH immunoreactivepeptides.

The results show that the intermediate copy number gave the highestproduction. The produced PTH was secreted completely to the growthmedium. The secreted products were concentrated from the growth mediumand analyzed on SDS-PAGE. A distinct band with the same molecular weightas hPTH standard was visible on the gel.

hPTH immunoreactive material was concentrated from the growth medium bypassage through a S Sepharose Fast flow column and elutedquantitatively. Recombinant hPTH was purified by reverse phase HPLC. Thecolumn was eluted with a linear gradient of acetonitrile/trifluoroaceticacid. A major peak (fractions 32 and 33) with the same retention time asstandard hPTH(1-84) was resolved into two peaks in a second HPLCpurification step. The major peak from the 2.HPLC eluted exactly asstandard hPTH(1-84) and co-chromatographed with hPTH(1-84) as onesymmetric peak.

SDS-PAGE of the peak fraction showed one band co- migrating with hPTHstandard suggesting that the recombinant PTH was essentially pure. Therecombinant hPTH was subjected to N-terminal amino acid analysis.

We were able to determine unambiguously 45 amino acids from theN-terminal end in the E. coli protein and 19 amino acids in the yeastprotein. The sequence was identical to the known sequence of hPTH. Thesequence analysis indicated that the recombinant PTH was more than 90percent pure. The recombinant hPTH from E. coli and Saccharomycescerevisiae was fully active in adenylate cyclase assay and also inducedhypercalcemia in rats after injection.

We have successfully expressed biologically active intact humanparathyroid hormone as a secretory peptide in Escherichia coli andSaccharomyces cerevisiae, and developed a down-stream purificationtechnology.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows all possible variations of the DNA sequence coding forhuman preproparathyroid hormone.

FIG. 2 shows the specific human preproparathyroid hormone DNA codingsequence of the clone pSShPTH-10.

FIG. 3 shows a DNA sequence coding for human preproparathyroid hormoneand having a double start codon at the 5' terminal end with flankingsequences in which are shown all possible variations of the DNA whichmay be present on the plasmid of the present invention.

FIG. 4 shows the specific human preproparathyroid hormone DNA codingsequence of the clone pSSHPTH-10 with flanking sequences.

FIG. 5 shows the actual amino acids sequence of the humanpreproparathyroid hormone for which the DNA sequence in close pSShPTH-10codes.

FIG. 6 shows the sequence of the MFα1-hPTH fusion gene with all possiblecombinations of the DNA coding for hPTH.

FIG. 7 shows the sequence of the MFα1-hPTH fusion gene.

FIG. 8 in panels a-c illustrate the analysis of expression products bySDS-PAGE and immonoblotting.

Saccharomyces cerevisiae transformed with a PTH cDNA carrying plasmidwas grown in liquid culture medium.

The secreted products were concentrated and analyzed on SDS-PAGE. Panela shown a silver stained gel with molecular size marker (lane S), hPTHstandard (lane P), and concentrated yeast growth medium (lane 1). Afterblotting onto a PVDF membrane, blots were probed with hPTH specificantibodies, one reactive against the aminoterminal part of the hormone(panel b), another reactive against the middle region of the hormone(panel c). Lanes in panel b and c are numbered as in panel a.

FIGS. 9A-9D show the purification of recombinant hPTH medium including:FIG. 9A, a chromatogram of the HPLC purification; in FIG. 9B achromatogram of the HPLC purification of fractions 32 and 33 from panel9A (the peak of the recombinant hPTH is indicated in black); FIG. 9C, anHPLC of one microgram standards hPTH (1-84); and 9D, a co-chromatogramof the recombinant PTH from panel 9B and one microgram standard of hPTH.

FIGS. 10A-10G. Construction of PPTH-M13-ΔEA/KQ.

FIG. 11. Schematic representation of the mutation introduced in the genefusion between the yeast α-factor prepro region and the humanparathyroid hormone.

FIG. 12. SDS PAGE of concentrated yeast growth medium containing mutatedand wild type hPTH. Aliquots of concentrated growth medium from yeaststrain BJ1991 transformed with the expression plasmids pαUXPTH-2⁹ (lane2) and pαUXPTH-Q26 (lane 1) were analyzed by 15% PAGE in the presence of0.1% SDS, and visualized by silver staining as described in ExperimentalProtocol.

Lane M shows a molecular size marker including a hPTH standard. Thelatter is marked with an arrow.

FIG. 13. panels a and b illustrate the purity of purified hPTH(1-84,Q26). Yeast growth medium from yeast strain BJ1991 transformedwith the expression plasmids pαUXPTH-Q26 were concentrated and purifiedby reversed phase HPLC as described in Experimental Protocol. The purityof the recombinant hormone was then analyzed by analytical HPLC (PanelA) and SDS PAGE (Panel B, lane 2). In Panel B the purified hPTH(1-84,Q36) is compared with the wild type hormone purified by two runson HPLC (lane 3). The molecular weight marker in lane M is the same asin FIG. 2. Lane 1 shows a reference PTH produced in E. coli.

FIG. 14. Two dimensional gelelectrophoretic analysis of hPTH (1-84,Q26).An aliquot of concentrated growth medium from yeast strain BJ1991transformed with the expression plasmids pαUXPTH-Q26 was separated on anacetic acid 15% PAGE. The two main bands (band 1 and 2) migrating closeto the hPTH standard were then cut out, equilibrated with SDS loadingbuffer and run into a second dimension 15% PAGE containing 0.1% SDS inseparate lanes in triplicate. This gel was divided in three and one partwas colored with silver (Panel A), one part blotted and treated withhPTH N-terminal region specific antibodies (Panel B) and one partblotted and treated with hPTH middle-region specific antibodies (PanelC). Lanes 1 and 2 show band 1 and 2, PTH_(e) is a reference hPTHproduced in E. coli, PTH_(C) is a commercial hPTH reference. Lane Sshows a molecular weight standard.

FIG. 15. Biological activity of hPTH (1-84,Q26). Recombinant hPTH(1-84,Q26) (▪) was purified on HPLC and assayed for biological activityin a hormone-sensitive osteoblast adenylate cyclase (AC) assay asdescribed in Materials and Methods. The experiments were carried out intriplicate determinations. hPTH (1-84) from Sigma (∘) and recombinantyeast hPTH (1-84) (▴) were used as references.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As indicated above, the present invention is directed to a plasmid forinsertion in E. coli containing DNA coding for human preproparathyroidhormone. The invention is also directed to the resulting transformed E.coli.

The invention further is directed to a plasmid for insertion into yeastwhich contains DNA coding for parathyroid hormone and which is derivedfrom the plasmid for insertion into E. coli. Finally, the invention isdirected to a transformed yeast from which parathyroid hormone may berecovered.

The invention further provides methods of producing and isolating theplasmids and transformed microorganisms. Poly(A) selected RNA wasisolated from human parathyroid adenomas collected immediately aftersurgery. The poly(A) RNA was enriched for correct size mRNA byultracentrifugation through sucrose gradients. Preproparathyroid hormoneof correct molecular weight was translated in vitro from this sizefractionated poly(A) RNA as judged by sodium dodecylsulphatepolyacrylamide gel electrophoreses after immuno-precipitation withantiparathyroid antiserum. The specific messenger RNA for the human PTHwas used as template for complementary DNA synthesis using oligo d(T)18as a primer and avian myoblastosis virus reverse transcriptase. Afterremoval of the RNA templates by alkali hydrolysis, the second strandcomplementary DNA was synthesized by incubating the purified firststrand DNA in the presence of the Klenow fragment of E. coli DNApolymerase I. The double stranded comlementary DNA was made blunt endedby the action of Aspergillus oryzae single strand specific endonucleaseS1 and complementary DNA longer than 500 base pairs was isolated afterneutral sucrose gadient centrifugation. Approximately 20 bases longd(C)-tail protrusions were enyzmatically added to the 3 ends of thecDNA. This modified complementary DNA was annealed to restrictionenconuclease PstI cleaved and d(G)-tailed vector pBR322. Resultingrecombinant plasmid DNA's were transformed into E. coli KI2 BJ 5183.Positive transformants were analyzed for by colony hybridization usingtwo different synthetic oligodeoxyribonucleotides which covered theN-terminal coding region as well as the 3' non-coding part of thehormone mRNA sequence, respectively. Six out of 66 clones that werepositive for both probes were submitted for detailed analysis byrestriction endonuclease mapping showing that they all were identicalexcept for some size heterogenity at the regions flanking the startcodon and the XbaI site 3' for the stop codon. One clone, pSShPTH-10,was subjected to DNA sequence analysis revealing a 432 nucleotide longhuman parathyroid hormone complementary DNA sequence inserted in thePstI site of pBR 322. The entire cDNA sequence was found to be identicalto the sequence previously described by Hendy, et al., supra, except fora 5 base pair deletion in front of the start codon.

FIG. 2 shows the human preproparathyroid hormone DNA sequence ofpSShPTH-10. This may be compared with FIG. 1, which shows all possiblevariations of the DNA sequence for human preparathyroid hormone withoutthe 5' double start codon. FIG. 3 shows the DNA sequence of the clone ofthe present invention with the flanking sequences. In a preferredembodiment, the plasmid for insertion in E. coli coding for humanpreproparathyroid hormone is pSShPTH-10, the DNA sequence of which,including the flanking sequence, is shown in FIG. 4.

The invention further provides a plasmid for insertion into yeastcontaining DNA coding for parathyroid hormone. The parathyroid hormonemay be human or animal parathyroid hormone, for example pig or bovineparathyroid hormone. The plasmid for insertion in yeast of the presentinvention may be recloned from plasmids containing DNA coding for humanor animal parathyroid hormone. In a preferred embodiment, the plasmidfor insertion in yeast contains DNA coding for human parathyroidhormone. As shown in the following examples, the hTPH sequence frompSShPTH-10 has been recloned and inserted in designed vectors forexpression in Saccharomyces cerevisiae.

pSShPTH-10 was digested to form a 288 bp BglII-XbaI fragment. Thisfragment was then subcloned into pUC19 between the BamHI and XbaI sites.The subclone was then digested with Dpn I, and the largest resultingfragment was isolated. The said fragment was then digested with SalI.

The plasmid pSSαLX5-hPTH1 that in yeast MAT cells leads to theexpression and secretion of PTH was constructed in three stages:

1. Construction of the yeast shuttle vector pL4 (which replicates inboth E. coli and Saccharomyces cerevisiae).

2. Cloning of a DNA fragment containing the yeast mating pheromone MFα1gene and its insertion into the yeast shuttle vector to make the pαLX5vector.

3. Insertion of a DNA fragment from the coding region of the hPTH geneof pSShPTH-10 into pαLX5 in reading frame with the prepro part of the MF1 gene, thereby producing the vector pSSαLX5-hPTH1.

The shuttle vector pL4 was constructed by inserting into pJDB207, anEcoRI-AvaII fragment containing the ADHI promoter isolated from PADHO40.A SphI fragment was then deleted, resulting in a plasmid pALX1. The PstIsite in the B-lactamase gene was deleted and the plasmid was partiallydigested with PvuI and BglI and ligated to a PvuI BglI fragment of pUC8,to form pALX2. After a further oligonucleotide insertion, the plasmidwas digested with HindIII and religated to form pALX4.

Total yeast DNA from the Y288C strain was digested with EcoRI, and the1.6-1.8 kb fragments isolated. These were ligated to EcoRI-cleavedpBR322, and E. coli was transformed. The clones were screened for MFα1inserts by oligonucleotide hybridization. The DNA selected thereby wasthen used to transform E. coli. The resulting plasmid pMFα1-1 wasdigested with EcoRI, made blunt ended by Klenow enzyme, and thendigested with BglII. The MFα1 fragment was isolated, and ligated to pL5(digested with BamHI, made blunt ended with Klenow enzyme, and digestedwith BglII) to yield pαLX5.

In order to insert the human PTH cDNA fragment into pαLX5, the pαLX5 wasdigested with HindIII, creating sticky ends and the site was made bluntended with the DNA polymerase I Klenow fragment and dNTP. The pαLX5 wasthen digested with SalI to create a sticky ended DNA complementary tothe SalI digested human PTH fragment described above.

The SalI digested human PTH fragment was then inserted into the SA1Idigested pαLX5. The resulting plasmid pSSαLX5-PTH was then inserted intoyeast, thereby transforming yeast so that the yeast produces andsecretes intact human parathyroid hormone. In a preferred embodiment,the transformed yeast is Saccharomyces cerevisiae.

As explained above, the invention provides alternate leader sequenceswhich may be used for the production of parathyroid hormone orderivatives thereof, as taught by the present invention. The method setforth above discloses the use of the α-factor leader sequence. However,other sequences may be used, at least one of which has been shown toprocess PTH with greater efficiency than does the entire α-factor leadersequence. It has been discovered that the deletion from the α-factorleader of a 12-base sequence which comprises the yeast STE13 recognitionsite produces a more efficient production mechanism for PTH and/or itsderivatives. pSSαUXPTH-ΔEA contains the α-factor hPTH fusion gene placedbetween the α-factor promoter and terminator, in which the regionencoding the Glu-Ala-Glu-Ala recognition sequence of the yeast STE13aminopeptidase has been deleted. As another example of an alternativeleader sequence, a leader sequence comprised of only the first nineteenamino acids of the α-factor is also used in the method of the presentinvention.

Also shown is an example of site specific mutagenesis changing the codonfor the amino acid 26 in the PTH gene, thereby transforming alysine-codon (K) to glutamine-codon (Q) using the Muta-Gene™ in vitromutagenesis kit from Bio-Rad. For this purpose, the plasmidpΔPTH-M13-ΔEA was used to transform the E. coli strain CJ236. Auracil-containing single-stranded DNA which was prepared from the phagewas annealed to a synthetic oligonucleotide, and second strain synthesiswas carried out with T4 DNA polymerase and ligation with T4 DNA ligase.The heteroduplex DNA was transformed into the E. coli strain MV1190 tobe repaired into a homoduplex by removal of uracil incorporated in theparental strand. Positive clones were verified by DNA sequencing and oneof these was called pΔPTH-M13-ΔEA/KQ. Finally, the entire expressioncassette between a BamHI and a filled-in EcoRI site was isolated fromthis vector construction and inserted into the BamHI and PvuII site ofthe yeast shuttle vector YEp24 and this final expression plasmid wasdesignated pSSαUXPTH-ΔEA/KQ.

A point mutation was introduced in the gene encoding the humanparathyroid hormone leading to a change of the 26th amino acid fromLysine (K26) to Glutamine (Q26). When this gene was expressed andsecreted in Saccharomyces cerevisiae using the α-factor fusion system,the full length hormone was found in the growth medium with nodegradation products present. This contrasts the situation when the wildtype gene is expressed in the same system. Then the major product is ahormone fragment hPTH(27-84), and only up to 20% of the immunoreactivesecreted material is hPTH(1-84). The yield after a two step purificationof the degradation resistant hormone was 5-10 fold higher than what wasobtained with the wild type hormone. The secreted hPTH(1-84,Q26) hadcorrect size, full immunological reactivity with two different hPTHspecific antibodies and correct N-terminal amino acid sequence.Furthermore, the introduced mutation had no effect on the biologicalactivity of the hormone as judged from its action in a hormone-sensitiveosteoblast adenylate cyclase assay.

Human parathyroid hormone (hPTH) is one of the key calcium regulatinghormones in the body. The hormone is produced in the parathyroid glandas a 115 amino acid prepro-peptide that is processed during secretion toan 84 amino acid mature hormone.¹ It acts primarily on kidney and bonecells, stimulating calcium back resorption and calcium mobilization,respectively.²⁻⁴ The hormone seems to exhibit differential catabolic aswell as anabolic effects and its overall physiological action isprobably to generate a positive calcium balance and enhance boneformation.

The area of potential utility includes possible use in treatment ofpostmenopausal osteoporosis as well as in prevention of postpartumhypocalcaemia in cows. Sufficient supplies of authentic recombinant hPTHare of considerable interest to evaluate such applications. hPTH is aneasily degraded polypeptide.

Already in the parathyroid gland large amounts of carboxyl-terminal PTHfragments are generated.¹ Structural studies have suggested that hPTHmay contain two domains with the easily cleaved region placed in aconnecting stalk between these domains.⁵ Not surprisingly therefore,degradation of hPTH has been a major problem when the hormone isexpressed in heterologous organisms. In E. coli low expression levelscombined with degraded hormone peptides of short half-life wereobserved.⁶⁻⁸ The most successful expression system for hPTH so far isSaccharomyces cerevisiae where the hormone is expressed as a secretorypeptide.² By that approach we were able to obtain significant amounts ofauthentic hPTH(1-84) with full biological activity. But even ifconditions were found which eliminated proteolytic attacks at some sitesin the putative stalk region of the hormone, a significant fraction ofthe secreted peptides was still cleaved after a pair of basic aminoacids found in the hPTH sequence reducing the yield of full lengthpeptide hormone. The cleavage site resembles that recognized by the yscFprotease (the KEX2 gene product).¹⁰,11 We reasoned that the eliminationof the putative yscF cleavage in hPTH could lead to a significant gainin the yield of undegraded hPTH secreted from yeast. In the presentreport we describe the removal of the putative yscF cleavage sites by invitro mutagenesis of the hPTH coding region. When the amino acid atposition 26 in hPTH was changed from Lysine (K26) to Glutamine (Q26),the major degradation product hPTH(27-84) previously observeddisappeared in the growth medium and the yield of full-length hormoneincreased 5- to 10-fold. The secreted degradation resistant hPTHC 1-84,Q26) had correct size, full immunological reactivity with two differenthPTH specific antibodies and correct N-terminal amino acid sequence.Furthermore, the introduced mutation had no effect on the biologicalactivity of the hormone as judged from its action in a hormone-sensitiveosteoblast adenylate cyclase assay.

The Saccharomyces cerevisiae strain used for the hPTH expression wasBJ1991 (a, trp1, ura3-52, leu2, prb1-1122, pep4-3). Yeast cells weretransformed by the lithium method¹², and transformants grown at 30° C.in YNBGC medium (0.67 percent yeast nitrogen base, 2 percent glucose, 1percent casamino acids (Difco).

The pαUWTH-2 plasmid used as a reference for expression of authentichPTH(1-84) is described.² In order to change the codon 26 in the hPTHgene from AAG (Lysine) to CAG (Glutamine), an α-factor hPTH gene fusionsubcloned in M13 mp19 (designated M13PTH-3 in ⁹) was modified by invitro mutagenesis using the "Mutagene™ in vitro mutagenesis kit"(Bio-Rad) based on the method of Kunkel et al.¹³. The mutagenizingoligonucleotide had the sequence 5'-GGCTGCGTCAGAAGCTGC-3' where allnucleotides except the ninth are complementary to the actual hPTHsequence. Positive clones were verified by DNA sequencing.¹⁴ One ofthose were picked and called M13PTH-Q26. The entire expression cassettebetween a BamHI and a filled in EcoRI site was finally isolated fromM13PTH-Q26 and inserted between the BamHI and PvuII site of the yeastshuttle vector YEp24.¹⁵ This expression plasmid was designatedpαUXPTH-Q26. The translation product from the hPTH gene between aminoacid 25 and 27 should now change from Arg-Lys-Lys to Arg-Gln-Lys.

Radioimmunoassay of hPTH in yeast culture media was carried out asdescribed.⁹,16 For electrophoretic analysis, yeast culture media wereconcentrated as previously described⁹ and separated on a 15 percentpolyacrylamide gel in the presence of SDS¹⁷, and either stained withsilver¹⁸ or further analyzed by protein blotting using Immobilon PVDFTransfer Membranes (Millipore) and the buffers of Towbin et al.¹⁹Reference hPTH(1-84) was purchased from Peninsula Laboratories (USA).Protein blots were visualized as described.⁹

The concentrated medium from the Sepharose S column was subjected tofurther purification by reversed phase HPLC using a Vydac proteinpeptide C18 column (The Separation Group, Hesperia, Calif., USA). Thecolumn was eluted with a linear gradient of acetonitrile/0.1 percenttrifluoroacetic acid.

Proteins to be sequenced was purified either by HPLC as described aboveor by SDS polyacrylamide gelelectrophoresis followed by blotting ontopolyvinylidene difluoride membranes.²⁰ Automated Edman degradation wasperformed on a 477A Protein Sequencer with an on-line 120Aphenylthiohydantoin amino acid analyzer from Applied Biosystems (FosterCity, Calif., USA). All reagents were obtained from Applied Biosystems.

The adenylate cyclase stimulating activity of the recombinant hPTH wasassayed as previously described⁹,21,22 hPTH(1-84) from Sigma was used asreference.

Different strategies could be envisaged to avoid the degradation ofparathyroid hormone during expression in heterologous organisms. Onerecently reported strategy is to express intracellularly in E. coli acro-lacZ-hPTH fusion protein that subsequently is cleaved by strong acidto give proline-substituted hPTH.²³ However, since secretion of thehormone in yeast seems to be a more efficient way of producing acorrectly processed hormone, and also is superior with respect todownstream processing, we rather adopted a strategy to improve thissystem. Only one major cleavage site is used during secretion in yeastwhen the cells are grown under proper conditions: after a pair of basicamino acids in position 25 and 26 in the hPTH sequence. This cleavagesite resembles that recognized by the yscF protease (the KEX2 geneproduct). We reasoned that a substitution of a glutamine for the lysine26, as illustrated in FIG. 11, ought to be a structurally conservativechange that should exclude the hormone as a substrate for the yscFprotease.

The yeast strain BJ1991 was transformed with the plasmids pαUXPTH-Q26containing the mutated hPTH coding region. One transformant was grown inYNBGC medium lacking uracil and the cell free medium was concentratedand analyzed in different gel systems. FIG. 12 shows a silver-stainedSDS polyacrylamide gel where concentrated medium from pαUXPTH-Q26transformed cells (mutated hgTH, lane 1) is compared with that frompαUXPTH-2 transformed cells (wild type hPTH, lane 2). In the latter casethe strongest band has a molecular mass lower than the standard hPTH,and previous microsequencing has shown that it corresponds to thehormone fragment hPTH(27-84). In the lane with the mutated product (lane1), this band is absent showing that the cleavage between amino acids 26and 27 has been totally eliminated as a result of the mutation. Now themajor product is a polypeptide that migrates close to the full lengthhPTH standard. Consistently, this band had a migration slightly fasterthan the standard in an anionic gel system and a migration slightlyslower than the standard in a cationic gel system in accordance with thesingle charge difference between the mutated (one positive charge less)and the wild type hormone. In addition to the main product a few weakerbands were present of apparently higher molecular mass which might beO-glycosylated forms of the hormone.

This hPTH(1-84,Q26) candidate was further analyzed by two dimensionalgel electrophoresis and protein blotting. In the first dimension aceticacid/urea gel a simple pattern with mainly two bands was found. Thesewere cut out and run on a second dimension SDS polyacrylamide gel. Thesilver stained second dimension gel as well as two protein blots probedwith different PTH antibodies, are shown in FIG. 14. The hPTH(1-84,Q26)candidate migrating closest to the hPTH standard in both dimensions,reacted with two hPTH specific antibodies raised against N-terminalregion and the middle/C-terminal region of the hPTH respectively.

The nature of the hPTH(1-84,Q26) candidate was finally confirmed byN-terminal amino acid sequencing, both directly on the polypeptide bandafter blotting onto a PVDF membrane filter, and after purification onreversed phase HPLC. Correct amino-terminal sequence was found in bothcases. Furthermore, the expected change from lysine to glutamine inposition 26 was confirmed by sequencing through this position.

Since the elimination of the internal cleavage of the secreted hPTHleads to fewer polypeptides with similar properties in the growthmedium, this form of the hormone could also be isolated by a simplifiedpurification procedure. Already in the first concentration step using aSepharose S column, a certain purification is achieved. All hPTHimmunoreactive material is retained, but some high molecular weightmaterial is removed in the pH6 wash of the Sepharose S column. Thisfirst concentrated eluate already contained more than 80 percenthPTH(1-84, Q26). Then, a single run on a reverse phase HPLC C18 column,was enough to give near homogeneous hPTH(1-84, Q26). The purity waschecked both by SDS polyacrylamide gelelectrophoresis and sensitivesilver-staining, and by analytical HPLC as illustrated in FIG. 13A. Asingle peak is found in the chromatogram (FIG. 13A), and a single bandwith only a trace of a closely migrating hPTH band (probably anO-glycosylated form of the hormone) could be seen in the SDSpolyacrylamide gel (FIG. 13B). When the yield of pure full lengthmutated hormone was compared with that of the wild type, 5 to 10 foldhigher yields were usually achieved. This is consistent with ourprevious estimate of the fraction of full length hormone (up to 20percent) obtained when the wild type is expressed.⁹

The biological activity of the secreted hPTH(1-84, Q26) was tested in ahormone-sensitive osteoblast adenylate cyclase assay.⁹,21,22 Thepurified hPTH(1-84, Q26) was analyzed for its ability to stimulate theadenylate cyclase activity of OMR 106 osteosarcoma cells above the basallevel. The quantitative analysis shown in FIG. 15, clearly demonstratesthat hPTH(1-84, Q26) has a stimulatory effect comparable to that of acommercial hPTH control. The stimulation curve practically coincideswith that of purified recombinant wild type hPTH(1-84). Consequently, nodifference in biological activity could be detected between the wildtype hormone and the degradation resistant mutated hormone.

We have shown that the easily degraded human parathyroid hormone can beexpressed in a correctly processed and intact form in Saccharomycescerevisiae after the introduction of a single, structurally conservativemutation in the 26th amino acid of the hormone. The increase in finalyield of pure full length hormone is 5- to 10-fold compared to what isobtained with wild type hormone expressed in the same system. Themutation also simplifies the downstream purification of the hormone. Aconcentration step followed by a single HPLC run was enough to give nearhomogeneous recombinant hormone.

We have previously described conditions of growth that eliminatessecondary cleavages in the protease sensitive "stalk" region of thehormone⁹. Here we describe how the final dibasic cleavage site can beeliminated. After introduction of the mutation, a form of the hormone isproduced that totally resists the frequent cleavage found in the wildtype hormone after the Arg25-Lys26 motif. The possible internal cleavageat putative dibasic amino acids is one of the severe drawbacks of theα-factor secretion system. To our knowledge this is the first reportedcase where this problem has been successfully overcome.

Previous reports have shown that the biological activity of the hormoneresides in the first third of the molecule in a minimum structurecomprised of amino acids 1-27. Furthermore, the triple basic amino acidmotif from position 25-27 seems to be conserved between the bovines²⁵,porcine²⁶ and human hormone²⁷. It was therefore not obvious that theintroduction of a mutation in position 26 would not destroy thebiological activity of hPTH. However, no difference between therecombinant hPTH products could be detected in the adenylate cyclaseassay, showing that the introduced mutation does not affect thebiological activity of the hormone.

hPTH is a multifunctional hormone with many potential uses, for examplein diagnostics and as a drug in veterinary medicine. A fragment of hPTHtogether with 1,25(OH)₂ vitamin D₃ has also been reported to induce boneformation in humans ²⁷,28 and one of the major areas of potential use ofa recombinant hPTH is therefore in the treatment of osteoporosis. Toevaluate such applications, sufficient supplies of recombinant hPTH areessential. In the present report we have described what we believe isthe most efficient way of producing full length biologically activeparathyroid hormone so far.

Moreover, the method of the present invention may be used to produceparathyroid hormone derivatives having parathyroid hormone agonistic orantagonistic activity. These derivatives include hormone analogs, suchas the example described above in which the lysine at position 26 issubstituted with glutamine, or may be fragments or extensions of thehormone, i.e., polypeptides having parathyroid hormone agonist orantagonist activity which are respectively shorter or longer than thehormone itself. Parathyroid hormone agonistic effect in this connectionwill be demonstrated by activation of adenylyl cyclase in bone cells andkidney cells. The in vivo effects of such activity mimic the effects ofnative parathyroid hormone with respect to plasma calcium concentrationalterations as well as the well known hormonal actions on calcium andphosphate re-absorption and excretion in the kidney. Furthermore, thePTH derivatives of the present invention having agonist activity shallalso have the capacity to reduce the alkaline phosphatase activity ofcertain osteoblast cell lines, and stimulate ornithine decarboxylaseactivity bone cells (UMR 106 cells) or chicken condrocyes and stimulateDNA synthesis in chicken condrocytes. Moreover, the derivatives shallhave the capability of blocking the action of parathyroid hormone itselfor of any of the other agonist derivatives.

The invention also provides alternate secretion signal sequences for thesecretion of the PTH hormone or its derivatives from yeast. As disclosedabove, parts of the MFα1 gene may be inserted into the plasmid of thepresent invention to cause the yeast to secrete the intact PTH hormoneor derivatives. However, other signal sequences will also function inthe methods of the present invention. The process of protein secretionrequires the protein to bear an amino-terminal signal peptide forcorrect intracellular trafficking, the sequence of which is termed"signal sequence". Two classes of signal sequences will function in theplasmids of the present invention, and will cause secretion of the PTHhormone or derivative from yeast: "optimalized consensus signalsequences and other functional signal sequences. An "optimalizedconsensus signal sequence" is any amino-terminal amino acid sequencethat is composed of the following three parts:

1. An amino-terminal positively charged region. The size of this regionmay vary from 1-20 amino acids. The only specific characteristic is apositive charge at physiological pH conferred by the presence of one tothree basic amino acids (Lys or Arg).

2. A hydrophobic core region. The size of this region may vary from 7-20amino acids, and it is predominantly composed of hydrophobic amino acids(Phe, Ile, Leu, Met, Val, Tyr, or Trp).

3. A polar COOH-terminal region composed of five amino acids (fromposition -5 to -1 relative to the cleavage site) that defines thecleavage site. The specific character of this region is that the aminoacid in position -1 must be a small neutral amino acid (Ala, Ser, Gly,Cys, Thr, or Pro), and that the amino acid in position -3 must be eithera hydrophobic amino acid (Phe, Ile, Leu, Met, Val) or a small neutralamino acid (Ala, Ser, Gly, Cys, Thr, or Pro).

See von Heijne, G. (1983) Patterns of Amino Acids near Signal-SequenceCleavage Sites." Eur. J. Biochem. 133, 17-21, and von Heijne, G. (1985)"Signal sequences. The limits of variation." J. Mol. Biol. 184, 99-105.However, Kaiser, C. A., Preuss, D., Grisafi, P., and Botstein, D. (1987)"Many Random Sequences Functionally Replace the Secretion SignalSequence of Yeast Invertase." Science 235, 312-217, found thespecificity with which signal sequences were recognized in yeast to below and that any amino-terminal peptide with a hydrophobicity above somethreshold value would function. Therefore, "functional signal sequence"is defined as any amino-terminal amino acid sequence that can directsecretion in yeast even if it does not fit all the criteria of anoptimal signal sequence.

Specific examples of signal sequences functional in yeast that conformto the description of an optimal signal sequence are:

1. Met,Lys,Ala,Lys-Leu,Leu,Val,Leu,Leu,Thr,A la, Phe-Val,Ala,Thr,Asp,Ala(Jabbar, M. A., and Nayak, D. P. (1987) "Signal Processing,Glycosylation, and Secretion of Mutant Hemagglutinins of a HumanInfluenza Virus by Saccharomyces cerevisiae." Molec. Cell. Biol. 7,1476-1485.) from a human influenza virus hemagglutinin.

2. Met,Arg,Ser-Leu,Leu,Ile,Leu,Val,Leu,Cys,P he,Leu,Pro-Leu,Ala,Ala,Leu,Gly (Jigami, Y., Muraki, M., Harada, N., andTanaka, H. (1986) "Expression of synthetic human-lysozyme gene inSaccharomyces cerevisiae: use of a synthetic chicken-lysozyme signalsequence for secretion and processing." Gene 43, 273-279.) from chickenlysozyme.

3. Met,Arg,Phe,Pro,Ser-Ile,Phe,Thr,Ala,Val,L eu,Phe,Ala,Ala-Ser,Ser,Ala,Leu,Ala (Ernst, J. F. (1988) "EfficientSecretion and Processing of Heterologous Proteins in Saccharomycescerevisiae is mediated solely by the Pre-Segment of α-factor Precursor."DNA 7, 355-360. Kurjan, J. and Herskowitz, I. (1982) "Structure of aYeast Pheromone Gene (MFa): OA putative α-factor Precursor contains fourTandem Copies of Mature α-factor". Cell 30, 933-934.) from yeastα-factor precursor.

A specific example of signal sequences functional in yeast that conformsto the description of a functional signal sequence isMet,Asn,Ile,Phe,Tyr,Ile,Phe,Leu,Phe,Leu,Ser,Phe,Val-Gln, Gly,Thr,Arg,Gly. Baldari, C., Marray, J. A. H., Ghiara, P., Cesareni, G.,and Caleotti, C. L. (1987) "A novel leader peptide which allowsefficient secretion of a fragment of human interleukin 1B inSaccharomyces cerevisiae." EMBO J. 6. 229-234. from Klyveromyces laciskiller toxin.

Finally, the invention provides three different steps which takentogether, represent an effective and convenient procedure forpurification of human recombinant parathyroid hormone (PTH). A cationexchange chromatography using S-Sepharose column as described in thetext, washed at pH 6 and eluted at pH 8.5. The immunoreactivity of theintact PTH migrates within the peak.

FIG. 9 shows high performance liquid chromatography (HPLC) of hPTH whichwas eluted with trifluoraecetic acid and a linear gradient ofacetonitril of 35-60%. The position of intact hPTH is indicated in thesecond HPLC step the acetonitril gradient has been changed to 40-45% andintact hPTH elutes as one symmetrical peak.

Although the methods of making the invention disclosed herein are shownin detail, these methods are presented to illustrate the invention, andthe invention is not limited thereto. The methods may be applied to avariety of other plasmids containing DNA coding for human or animal PTHto produce the plasmids for insertion in yeast of the present invention.

The plasmids of the present invention and transformed microorganismswere produced as set forth in the following examples.

EXAMPLE 1

Isolation of mRNA and synthesis of complementary DNA (cDNA) of humanparathyroid hormone.

Starting material for the invention was parathyroid adenomas obtainedfrom patients by surgery. The parathyroid tissue was placed on dry icedirectly after removal and transported to a laboratory for preparationof RNA. The frozen tissue was homogenized with an ultra Turaxhomogenizer in the presence of 4 M Guanidinium thiocyanate and the RNAcontent was recovered by serial ethanol precipitations as described byChirgwin, J. M., Przybyla, A. E., MacDonald, R. J. and Rutter, W. J., 18Biochemistry 5294-5299 (1979). The RNA preparation was applied to oligod(T) cellulose affinity chromatography column in order to enrich forpoly(A) containing mRNA. The poly(A) rich RNA was further enriched forparathyroid hormone (PTH) mRNA sized RNA by ultracentrifugation througha 15-30% linear sucrose gradient. The resulting gradient was dividedinto 25 fractions and every third fraction was assayed for PTH mRNAcontent by in vitro translation followed by immunoprecipitation withanti PTH antiserum (Gautvik, K. M., Gautvik, V. T. and Halvorsen, J. F.,Scand. J. Clin. Lab. Invest. 43, 553-564 (1983)) and SDS-polyacrylamidegel electrophoresis (Laemmeli, U.K., 227 Nature 680 (1970)). The RNAfrom the fractions containing translatable PTH mRNA was recovered byethanol precipitation. This RNA, enriched for PTH mRNA, was used as atemplate for cDNA synthesis using oligo d(T)18 as a primer and avianmyoblastosis virus reverse transcriptase for catalysis of the reaction(Maniatis, T., Fritsch, E. F. and Sambrook, J., Molecular Cloning pp.230-243 (1982)). After first strand synthesis, the RNA templates wereremoved by alkali hydrolysis. The second strand cDNA was synthesized byincubating the purified first strand cDNA in the presence of the Klenowfragment of E. coli DNA polymerase I (Maniatis, supra). This in vitrosynthesized double stranded cDNA was made blunt ended by the action ofAspergillus oryzae single strand specific endonuclease S1 (Maniatis,supra). The blunt ended double stranded cDNA was size fractionated overa 15-30% neutral sucrose gradient. The size distribution of eachfraction was estimated by agarose gel electrophoresis together withknown DNA fragment markers. Fractions containing cDNA larger thanapproximately 500 base pairs were pooled and the cDNA content wascollected by ethanol precipitation.

EXAMPLE 2

Cloning of cDNA PTH in plasmid pBR 322 and transformation of E. coli K12BJ5183.

An approximate 20 base long d(C)-tail protrusion was enzymatically addedto the 3' ends of the cDNA by the action of terminal deoxynucleotidyltransferase (Maniatis, supra). The d(C)-tailed cDNA was annealed torestriction endonuclease Pst I cleaved and d(G)-tailed vector pBR322 andthe resulting recombinant plasmid DNA's were transformed into E. coliK12 BJ 5183 cells which were made competent by the method of Hanahan,D., 166 J. Mol. Biol. 166, 557-580 (1983). A total of 33,000transformants were analyzed for PTH cDNA content by colony hybridization(Hanahan, D. and Meselson, Gene 10, 63 (1980)).

Two to three thousand transformants were plated directly on each 82 mmdiameter nitrocellulose filter, placed on top of rich medium agar platescontaining tetracycline, and incubated at 37 degrees Centigrade untilapproximately 0.1 mm diameter colonies appeared. Duplicate replicas ofeach filter was obtained by serial pressing of two new filters againstthe original filter. The replica filters were placed on top of newtetracycline containing agar plates and incubated at 37 degreesCentigrade until approximately 0.5 mm diameter colonies appeared. Themaster filter with bacterial colonies was kept at 4 degrees Centigradeplaced on top of the agar plate and the duplicate replica filters wereremoved from the agar plates and submitted to the following colonyhybridization procedure.

EXAMPLE 3

Characterization of bacterial clones containing recombinant cDNA PTH andof the DNA sequence of clone pSSHPTH-10.

The cells in the respective colonies were disrupted in situ with alkaliand sodium chloride leaving the DNA content of each bacterial cloneexposed. The procedure allows the DNA to bind to the filter after whichit was neutralized with Tris-buffer and dried at 80 degrees Centigrade.The majority of cell debris was removed by a 65 degree Centigrade washwith the detergent sodium dodecylsulphate (SDS) and sodium chlorideleaving the DNA bound to the filters at the position of the formerbacterial colonies. The filters were presoaked in 6× SSC (0.9 M NaCl,0.09M Na-citrate), 1× Denhart's solution (0.1 g/ml FIcoll, 0.1 g/mlpolyvinyl pyrrolidone, 0.1 g/ml bovine serum albumin), 100 g/ml herringsperm DNA, 0.5% SDS and 0.05% sodium pyrophosphate for 2 hours at 37degrees Centigrade (Woods, D. E. 6 Focus Vol. No. 3. (1984)).

The hybridization was carried out at 42 degrees Centigrade for 18 hoursin a hybridization solution (6× SSC, 1× Denhart's solution, 20 g/ml tRNAand 0.05% sodium pyrophophate) supplemented with 32P-labelled DNAprobe.(Woods supra).

The DNA used as a hybridization probe was one of two different syntheticoligodeoxyribonucleotides of which the sequences were deduced from thepublished human PTH cDNA sequence of Hendy, supra. The first probe was a24-mer oligonucleotide originating from the start codon region of thehuman preproPTH coding sequence having a nucleotide sequence readingTACTATGGACGTTTTCTGTACCGA. The second oligonucleotide was a 24-merspanning over a cleavage site for the restriction endonuclease XbaIlocated 31 nucleotides downstream of the termination codon and consistedof the nucleotide sequence CTCAAGACGAGATCTGTCACATCC.

Labelling was carried out by transfer of 32 P from 32 P-γ-ATP to the 5'end of the oligonucleotides by the action of polynucleotide kinase(Maxam, A. M. and Gilbert, W., 65 Methods Enzymol., 499 (1980)).

The hybridized filters were washed in 6× SSC, 0.05% sodium pyrophosphateat 42 degrees Centigrade prior to autoradiography. Sixty-six clones werefound to be positive for both probes as judged from hybridization toboth copies of the duplicate replica filters. All those were picked fromthe original filters with the stored cDNA library and amplified forindefinite storage at -70 degrees Centigrade. Six of these were chosenfor plasmid preparation and a more detailed analysis by restrictionendonuclease mapping, showing that all were identical except for somesize heterogeneity at the regions flanking the start codon and Xba Isite, respectively.

EXAMPLE 4

Clone RBShPTH-10.

One clone, pSShPTH-10, was subjected to DNA sequence analysis accordingto the method of Maxam and Gilbert, supra. This clone consists of a 432base pair long PTH cDNA sequence inserted in the Pst I site of pBR322having 27 G/C base pairs at the 5' end and 17 G/C base pairs at the 3'end. The complete DNA sequence of the cDNA insert of pSSHPTH-10 is shownin FIG. 4. It is identical to the sequence of Hendy, et al., supraexcept for a five base pair deletion right in front of the start codon,changing the published (Hendy, supra) start-stop (ATGTGAAG) signal(deletion is underlined) preceding the used start codon (ATG) to adouble start signal (ATGATG).

EXAMPLE 5

Construction of the yeast shuttle vector pL4.

Before the hPTH-yeast-expression project was initiated, a family ofgeneral yeast expression vectors were developed. One of these, pL4,later was used to make pSS LX5-hPTH1, as described below:

The plasmid pJDB207, constructed by Beggs, J. D., "Multiple-copy yeastplasmid vectors,, Von Wettstein, D., Friis, J., Kielland-Brandt, M. andStenderup, A. (Eds) Molecular Genetics in Yeast (1981), Alfred BenzonSymposium Vol. 16, 383-390, was chosen as the basis for the generalexpression vectors. It contains an EcoRI fragment of the yeast 2 micronDNA inserted into the pBR322 derivative pAT153. It also contains theyeast LEU2 gene. The copy number of pJDB207 in yeast cir⁺ cells is veryhigh relative to that of other plasmids and it is unusually stable afternon-selective growth in a cir₊ strain, Parent, S. A., Fenimore, C. M.,and Bostian, K. A. "Vector Systems for the Expression, Analysis andCloning of DNA Sequences in S. cerevisiaes. 1 Yeast 83-138 (1985);Erhart, E. and Hollenberg, C. P., "The Presence of a Defective LEV2 Geneon 2 Micron DNA Recombinant Plasmids of Saccharomyces cerevisiae isResponsible for Curing and High Copy Number," 156 J. Bacteriol. 625-635(1983). These properties are related to a partial defective promoter inthe selective marker gene LEU2 (often named LEU2d, d for defective),Erhart et al., supra, which is not changed in the following constructs.

A 1260 base pair EcoRI-AvaII fragment containing the ADHI promoter wasisolated from the plasmid pADHO40. After a fill in reaction with theKlenow fragment of DNA polymerase I and all four dNTPs, BamHI linkerswere attached and the fragment was cloned into the unique BamHI site ofpJDB207. From the plasmid with the promoter in a counterclockwisedirection, a 1050 base pair SphI fragment was then deleted (from theSphI site in pJDB207 to the SphI site in the promoter fragment) leavingonly a single BamHI site. This plasmid was designated pALX1.

Then the PstI site in the B-lactamase gene of pALX1 was eliminatedwithout inactivating the gene. pALX1 was digested to completion withPstI and nuclease S1 to destroy the PstI site, and then subjected to apartial digestion with PvuI BglI. At the same time a 250 base pair PVUIBglI fragment was isolated from pUC8, Vierira, J. and Messing, J. 19Gene 259 (1982), that contains the corresponding part of a B-lactamasewithout a PstI site. This was ligated to the partially digested pALX1.In all the ampicillin resistant clones isolated the B-lactamase gene hadbeen restored by incorporating the pUCS fragment. This plasmid wascalled pALX2.

The following oligonucleotide was purchased from Prof. K. Kleppe,University of Bergen, and inserted into the BamHI site of pALX2:

         Bg1II   *     * *  HindIII                                                                                   GATCAGATCTGCAGGATGGATCCAAAGCTT                                                     : initiation codon                       TCTAGACGTCCTACCTAGGTTTCGAACTAG  * : optimal ATG context                         PstI     BamHI                                                      

Plasmids with the proper orientation were isolated and designated pALX3.

Finally the pALX3 was digested with HindIII and religated to delete aHindIII fragment of 480 base pairs. The resulting vector is calledpALX4.

pL4 is a derivative of pALX4 in which the ADHI promoter is deleted. pL4was used as a basis for the insertion of other promoters. pALX4 wasfirst digested with BglII and SalI. The resulting sticky ends werefilled-in with the Klenow fragment of DNA polymerase I and 4 dNTPsfollowed by religation. By this treatment the ADHI promoter iseliminated and the BglII site regenerated to give the vector pL4.

EXAMPLE 6

Construction of DRLX5.

The gene for the yeast mating pheromone MFα1 was first cloned by Kurjan,J. and Herskowitz, I., Structure of a Yeast Pheromone Gene (MFα): APutative-factor Precursor Contains Four Tandem Copies of Mature-factor".30 Cell, 933-943 (1982). The published sequence was used to reclone theMFα1 gene. Total yeast DNA from the strain Y288C was digested with EcoRIand digestion products in the size range from 1.6 to 1.8 kb wereisolated from a preparative agarose gel. These were then ligated todephophorylated EcoRI cleaved pBR322 and used to transform E. coliBJ5183. The resulting clones were screened for MFα1 gene inserts byhybridization to a labeled oligonucleotide of the following composition:

TGGCATTGGCTGCAACTAAAGC

DNA from purified positive clones was then used to transform E. coliJA221 from which plasmid DNA was prepared. The plasmid used in thefollowing constructs was pMFα1-1.

pMFα1-1 was digested with EcoRI, filled-in with the Klenow fragment ofDNA polymerase I and 4 dNTPs, phenol extracted and digested with BglII.The 1.7 kb MF 1 gene fragment was isolated from an agarose gel. Beforeinserting it into the yeast shuttle vector, the HindIII site of pL4 waseliminated by HindIII digestion, Klenow fill-in reaction and religationto give the pL5 shuttle vector. pL5 was digested with BamHI, filled-inwith the Klenow fragment of DNA polymerase I and 4 dNTPs, phenolextracted and digested with BglII. After purification on gel it wasligated to the MFα1 fragment to give the expression vector pαLX5.

EXAMPLE 7

Construction of pSS LX5-HPTH1.

A 288 base pair BglII XbaI fragment from the pSSHPTH-10 plasmid wasisolated and subcloned in pUC19 using the BamHI and XbaI site of thisvector. This subclone designated pUC-HPTH, was digested with DpnI andthe largest fragment isolated. This fragment was then digested with SalIand the smallest of the two resulting fragments was again isolated,yielding a sticky end on the SalI cut side and a blunt end at the DpnIcut side.

pαLX5 was digested with HindIII, filled-in with the Klenow fragment ofDNA polymerase I and 4 dNTPs, phenol extracted and digested with SalI.After purification from gel, it was ligated to the hPTH fragmentdescribed above. The resulting clones had the HindIII site regeneratedverifying that the reading frame was correct. This plasmid calledpSSαLX5-hPTH1. The sequence of the MFα1-hPTH fusion gene is shown inFIG. 6.

EXAMPLE 8

Expression And Secretion Of HPTH In Yeast.

The yeast strain FL200 (, ura3, leu2) was transformed with the plasmidspαLX5 and pSSαLX5-hPTH1 using the spheroplast method. One transformantof each kind was grown up in leu medium and aliquots of the cell-freemedium were analyzed by SDS-PAGE developed by silver-staining. Two majorbands were seen in the medium from the pSSαLX5-H1 transformant that werenot present in the medium from the p LX5 transformant: one band ofapproximately 9000 daltons, the expected size of HPTH, and one band ofapproximately 16000 daltons that could correspond to an unprocessedMFα1-hPTH fusion product. Both polypeptides reacted with antibodiesagainst human PTH in a manner identical to the native hormone.

The examples are included by way of illustration, but the invention isnot limited thereto. While the above examples are directed to providinga S. cerevisiae which produces and excretes human parathyroid hormone,the method of the present invention may be applied to produce a plasmidcontaining DNA coding for parathyroid hormone from any species. Further,said plasmid may be inserted into any species of yeast. The inventionthus is not limited to S. cerevisiae.

The cloned human parathyroid hormone produced by the yeast of thepresent invention has a variety of known and potential uses. Forexample, it is current medical theory that human parathyroid hormonewill be highly effective in treating osteoporosis. Geneticallyengineered parathyroid hormone may be useful in an analytical kit formeasuring parathyroid hormone levels in humans and animals. Humanparathyroid hormone or fragments thereof may also be used for treatmentof humans or animals displaying reduced or pathologically altered bloodcalcium levels. It is anticipated that many other uses will bediscovered when genetically engineered parathyroid hormone is availablein large quantities, for example as a result of the present invention.

EXAMPLE 9

Deletion of the STE 13 recognition sequence positioned N-terminal forthe parathyroid hormone.

In order to delete the STE13 recognition sequence (Glu-Ala-Glu-Ala)located immediately N-terminal to PTH by site directed in vitromutagenesis of the fusion gene, a 1495 bp XbaI fragment was isolatedfrom pSSαLX5-PTH. This contained the α-factor promoter (MFaprom), theα-factor leader sequence (PP) and the human PTH gene (hPTH) includingthe stop codon. The fragment was subcloned into M13 mp19 to give theplasmid p PTHX-M13. An oligonucleotide with the sequenceGGATAAAAGATCTGTGAG was made where the first ten nucleotides arecomplementary to the sequence of the α-factor leader in pαPTHx-M13 justproceeding the Glu-Ala-Glu-Ala coding region, and the last eightnucleotides are complementary to the beginning of the human PTHsequence. When this oligonucleotide was annealed to single-stranded DNAprepared from the recombinant phage, the following heteroduplex wasgenerated:

    oligonucleotide: 5'-GGATAAAAGATCTGTGAG-3'                                        - p PTHx-M13       3'-CCTATTTTCTAGACACTC-5'                                                              C   A                                                                        T     G [to be removed]                                                       CCGACTTC                                           translation product . . . AspLysArgSerVal . . .                                                                            (upper)                                           . . . AspLysArgGluAlaGluAlaSerVal . . . (lower)        

After second strand synthesis and ligation with the Klenow fragment ofDNA polymerase I and T4 DNA ligase, closed circular heteroduplex DNA wasisolated by sedimentation through an alkaline sucrose gradient asdescribed in Carter, P., Bedouelle, H., Waye, M. M. Y., and Winter, G.(1985) Noligonucleotide site-directed mutagenesis in M13. Anexperimental manual," MRC Laboratory of Molecular Biology, Cambridge CB22QH., the disclosure of which is hereby incorporated by reference. Theheteroduplex DNA was used to transform a BMH 71-18 mutL strain of E.coli defective in mismatch repair (kindly provided by Dr. G. Winter).Positive clones with the looped out sequence 3'-CTCCGACTTCGA-5' deletedwere identified by colony hybridization using the mutagenizingoligonucleotide as the probe and by DNA sequencing. The plasmid in theseclones was designated pαPTHx-M13ΔEA.

The α-factor transcription terminator was then inserted into one of thepositive M13 clones as a SalI HindIII fragment isolated from pMFΔ1, togive a plasmid called pαPTH-M13-ΔEA. The entire expression cassettebetween a BamHI and a filled-in EcoRI site was finally isolated frompαPTH-M13-ΔEA and inserted between the BamRI and PvuII site of the yeastshuttle vector YEp24 by the method described in Botstein, D., Falco, S.C., Stewart, S. E., Brennan, M., Scherer, S., Stinchcomb, D. T., Struhl,K., and Davis, R. W. (1979) Gene 8, 17-24, which is hereby incorporatedby reference. This expression plasmid was designated pSSαUXPTH-ΔEA.

EXAMPLE 10

Conversion of intact hPTH by substitution of lysine with glutamine atposition 26. designated PTHQ₂₆,

In order to change the amino acid at position 26 in the human PTH fromlysine to glutamine, the fusion gene in pαPTH-M13-ΔEA was furthermodified by in vitro mutagenesis using the "Muta-gene™ in vitromutagenesis kit" obtained from Bio-Rad based on the method of Kunkel;Kunkel, T. A., Roberts, J. D., and Sakour, R. A. (1987) "Rapid andefficient site-specific mutagenesis without phenotypic selection" inMethods of Enzymology, (Wu, R., and Grossman, L., eds.) vol. 154, pp367-381, which is hereby incorporated by reference. The E. coli strainor CJ236 (dut, ung, thi, rel A; pCJ105 (Cm^(r))) was transformed withthe pαPTH-M13-ΔEA plasmid. The single-stranded DNA that was preparedfrom the phage contained a number of uracils in thymine positions as aresult of the dut mutation (inactivates dUTPase) and the ung mutation(inactivates the repair enzyme uracil N-glycosylase). An oligonucleotidewith the sequence GGCTGCGTCAGAAGCTGC was made where all nucleotidesexcept the ninth are complementary to an internal PTH sequence inpΔPTHx-M13. When this oligonucleotide was annealed to thesingle-stranded DNA, the following heteroduplex was generated:

                                         C                                                                              |  |                    oligonucleotide:         5'-GGCTGCGT  CAGAAGCTGC-3'                            - pαPTH-M13-ΔEA                    3'  . . . ccgacgca                                                     tcttcgacg . . . 5'                                                      |  |                                                         T                                          - Translation product    . . . LeuArgGlnLysLeu . . . (upper)                                       . . . LeuArgLysLysLeu . . . (lower)               

After second strand synthesis and ligation with T4 DNA polymerase and T4DNA ligase, the heteroduplex DNA was transformed into the E. coli strainMV1190 ((lac-pro AB), thi, sup E, Δ(srl-rec A)306::Tn10(tet^(r))[F': traD36, pro AB, lac I^(q) Z M15]) which contains a proficient uracilN-glycosylase. During the repair process in this host eliminating theuracils in the paternal strand, the in vitro synthesized strand willserve as a repair template conserving the mutation. Positive clones wereverified by DNA sequencing. One of those were picked and calledpαPTH-M13-ΔEA/KQ. The entire expression cassette between a BamHI and afilled-in EcoRI site was finally isolated from pαPTH-M13-ΔEA/KQ andinserted between the BamHI and PvuII site of the yeast shuttle vectorYEp24.

This expression plasmid was designated pSSαUXPTH-ΔEA/KQ.

EXAMPLE 11

Expression and secretion of hPTHQ₂₆ in yeast.

The yeast strain BJ1991 (α,Leu2,wa3-52,trpl,pr67-112,pep4-3) wastransformed with the plasmids pSSαUXPTH-ΔEA and pSSαUXPTH-ΔEA/KQ usingthe lithium method. One transformant of each kind was grown in mediumlacking uracil and the cell free medium was analyzed as described below.

EXAMPLE 12

Purification of heterologous hPTH from yeast medium concentration andpurification by S-Sepharose A fast flow.

Samples of cell free yeast medium (1-10 l) (containing 1% Glucose, 2%casamino acid, 134% yeast nitrogen base w/o amino acids, 60 mg/ml trp,180 kg/i) were adjusted to pH 3.0 and run through a 10 ml×10S-Sepharose^(R) (Pharmacia AB) fast flow column, pre-equilibrated with0.1M glycine pH 3.0. The loaded column was eluted by 13 ml 0.1M aceticacid buffered to pH 6.0, followed by 20 ml 0.1M NH₄ HC)₃ pH 8.5. Thepeptides eluted from the column were monitored by a Pharmacia opticalunit (Single path monitor UVI, Pharmacia AB, Uppsala, Sweden) at 280 nm,and collected in 2 ml fractions by an LKB 2070 Ultrorac II fractioncollector (LKB, AB, Bromma, Sweden).

EXAMPLE 13

Purification by HPLC.

Collected fractions from S-Sepharose fast flow chromatography weresubjected to further purification by reversed phase HPLC using a 25cm×4.2 cm Vydac protein peptide C18 column (The Separations Group,Hesperia, California, USA) and an LDC gradient mixer, LDC contamertricpumps model I and III with a high pressure mixing chamber and LDCspectromonitor III with variable UV monitor. (LDC Riviera Beach FL,USA). Chromatograms were recorded by a Vitatron 2 channel recorder. Theanalytical conditions were as follows:

First HPLC purification step:

Gradient: 35-60% B, 60 min., linear

A: 0.1% trifluoroacetic acid (TFA)

B: 70% acetonitril in A (ACN)

Flow: 1.0 ml/min

Detection: UV 220 nm

Second HPLC purification step:

Same as first step, with the following modification:

Gradient: 40-45% B 60 min; linear.

EXAMPLE 14

Assessment of the hPTHQ₂₆ product.

This PTH analog was verified to represent the designed product byN-terminal amino acid sequence analysis including amino acid no. 30 andshown to be hPTH identical except for the lysine to glutaminesubstitution at position 26.

Moreover, the resulting amino acid composition had the expectedalterations, in that the sequence contained one residue less of lysineand one residue more of glutamine.

Its biological activity was assessed after purification by testing theeffect of synthetically bought human parathyroid hormone fitures incomparison to the recombinant analogue which was equally potent instimulating the adenylyl cyclase of bone cell membranes from ratcalveria as well as from an osteosarcoma cell line.

EXAMPLE 15

Additional examples of amino acid substitutions by site specific invitro mutagenesis.

By the above method, it is possible to obtain any amino acidsubstitution or sequences of amino acid alterations in the PTH molecule.By use of the "MutaGene™ in vitro mutagenesis kit" and syntheticoligonucleotides with the desired sequence corresponding to the aminoacid alteration(s), this may be carried out. Each of theseoligonucleotides can be annealed to the single-stranded DNA in order togenerate a hetroduplex as indicated above.

Followed by second strand synthesis and ligation with T4 DNA polymeraseand T4 DNA ligase, the heteroduplex DNA is transformed into the E. colistrain MV 1190 with specifications as stated above. In each of thesecases, the repair process in this bacterial host will eliminate theuracils in the parenteral strands and at the same time, the in vitrosynthesized strand will serve as a repair template whereby theintroduced DNA changes will be conserved. All the positive clones willbe DNA sequenced and the expression cassettes isolated as describedabove and inserted into the yeast shuttle vector YEp 24 fortransformation of Saccharomyces cerevisiae.

This general approach with the specific alterations as indicated,enables the generation of any desired PTH peptide and PTH like peptide.For example, amino acid substitutions, deletions, insertions orextensions confined within the first 26 amino acids in the N-terminalregion can produce agonists with increased affinity for the PTHreceptors as well as antagonists which bind to the receptor, but arebiologically inactive. The mid-region or the C-terminal part of themolecule is of importance for modifying the binding of PTH to thedifferent receptors in bone cells and the kidney. Changes in either ofthese regions produce an increased or diminished binding affinity to thereceptors in hone cells and the kidney, and this may proposespecialization in binding characteristics so that the PTH derivativecould bind and function only in bone cells or in the kidney, oralteration, i.e., stimulation or blockade, of the biological activity atone or both receptor sites.

The inventions have been described herein with reference to certainpreferred embodiments. However, as obvious variations thereon willbecome apparent to those skilled in the art, the inventions are not tobe considered limited thereto.

EXAMPLE 16

Comparison of the Biological Activity of Human Parathyroid Hormone (hPTH1-84, Bachem Fine Chemicals. Cal. USA) with OPTH

The purpose of this study was to compare the biological activity of therecombinant QPTH with the standard PTH preparation of Bachem human PTH(1-84). We examined the ability of the two agents to inducehypercalcemia in rats. Both the maximum plasma calcium levels as well asthe duration of action was monitored.

Methods:

Male Wistar rats (150-200) were parathyroidectomized usingelectrocautery 18 hours before the start of the experiment. The animalswere fasted overnight, and anesthetized the next day using hypnormdormicum (0.2 ml per rat). The carotid artery was cannulated usingpolyethylene-50 tubing. The cannula was connected to a syringecontaining Ringers Acetate, 4% bovine serum albumin (BSA), and 25 unitsheparin/ml. Five minutes after injection of 200 Il of the heparinizedRingers, a baseline blood sample was drawn (300 Il). The animals weretrachesostomized to prevent respiratory failure due to damage to therecurrent laryngeal nerve running through the thyroid gland. The PTH wasthen injected subcutaneously, in a volume of 200 Il. Both hPTH and QPTHhad been dissolved into 50 Il of 0.01 N acetic acid, allowing at leastone half hour for complete dissolution. After dissolving in the aceticacid, the agents were brought up in 450 Il of Ringers Acetate containing1% BSA. Blood samples were then drawn at 1, 2, 3, and 4 hours after theinjection of the PTH. The rats were reheparinized 5 minutes beforedrawing each blood sample using 200 Il of the heparinized Ringerssolution.

The blood samples were centrifuged in a clinical centrifuge for 10minutes, then the plasma was analyzed for calcium using a Cobasautoanalyzer.

Both the Bachem hPTH and the QPTH induced hypercalcemia in the rats toabout the same degree and lasting about 2 hours. No significantdifference in the calcium response was seen until 4 hours after theinjections. Then the QPTH maintained the serum calcium better (p<0.05)than synthetic Bachem PTH.

The zero time plasma calcium (baseline) indicates the time of PTHinjection and was set equal to zero. The changes in plasma calcium fromzero are given as positive or negative values depending on the change(increase or reduction) in the measured values.

    ______________________________________                                        Time after injection (hrs)                                                      [calcium mg/100 ml from baseline]                                                          Median values                                                  Preparation    1      2        3    4 hours                                   ______________________________________                                        Bachem hPTH    +0.45  +0.30    -0.20                                                                              -0.70*                                      baseline: 6.84 ± 0.30                                                      (mg/100 ml)                                                                   QPTH +0.55 +0.25 0.0 -0.50                                                    baseline: 7.011 ± 0.29                                                     (mg/100 ml) (n = 7)                                                         ______________________________________                                         *a significant difference of p 0.05 (Wilcoxon, twosided test)            

REFERENCES

1 Cohn, D. V., and Elting, J. 1983. Biosynthesis, Processing, andSecretion of Parathormone and Secretory Protein-I. In Recent Progress inHormone Research (Greep, R. O., ed.) vol. 39, pp. 181-209, AcademicPress, NY.

2 Norman, A. W., Roth, J., and Orci, L. 1982. The vitamin D endocrinesystem--steroid metabolism, hormone receptors, and biological response(calcium binding proteins). Endocr. Rev. 3, 331-366.

3 Morel, F. 1983. Regulation of Kidney Functions by Hormones: A NewApproach. In Greep, R. O. (Ed.), Recent Progress in Hormone ResearchAcademic Press, NY, vol. 39, pp. 271-304.

4 Ay Potts, J. T., Kronenberg, H. M., and Rosenblatt, M. 1982. Adv.Protein chem. 32, 323-395.

5 Fiskin, A. M., Cohn, D. V., and Peterson, G. S. 1977. J. Biol. Chem.252, 8261.

6 Born, W., Freeman, M., Hendy, G. N., Rapoport, A., Rich, A., Potts, J.T. Jr., and Kronenberg, H. M. 1987. Human preproparathyroid hormonesynthesized in Escherichia coli is transported to the surface of thebacterial inner membrane, but not processed to the mature hormone. Mol.Endocr. 1, 5-14

7 Morelle, G., and Mayer, H. 1988. Biochim. Biophys. Acta 950, 459-462

8 Rabbani, S. A., Yasuda, T., Benett, H. P. J., Sung, W. L., Zahab,. D.M., Tam, C. S., Goltzman, D., and Hendy, G. N. 1988. Recombinant HumanParathyroid Hormone Synthesized in Escherichia coli. Purification andCharacterization. J. Biol. Chem. 263, 1307-1313

9 Gabrielsen, O. S., Reppe, S., Sletten, K., and Oyen, T. B., Sather,O., Hogset, A., Blingsmo, O. R., Gautvik, V. T., Gordeladze, J. O.,Alestrom, P., and Gautvik, K. M. 1989. Expression and secretion of humanparathyroid hormone in Saccharomyces cerevisiae.

Submitted.

10 Bussey, H. 1988. Proteases and the Processing of Precursors toSecreted Proteins in Yeast. Yeast 4, 17-26

11 Fuller, R. S., Sterne, R. E., and Thorner, J. 1988. Enzymes requiredfor yeast prohormone processing Ann. Rev. Physiol. 50, 345-362

12 Carter, B. L. A., Irani, M., Mackay, V. L., Seale, R. L.,Sledziewski, A. V., and Smith, R. A. 1987. Expression and secretion offoreign genes in yeast. In DNA cloning Volume III. A practical approach.(Glover, D. M., ed.) pp. 141-161, IRL Press, Oxford.

13 Kunkel, T. A., Roberts, J. D., and Zakour, R. A. 1987. Methods inEnzymol.

14 Sanger, F. et al. 1977. Proc. Natl. Acad. Sci. USA 74, 5463

15 Botstein, D., Falco, S. C., Stewart, S. E., Brennan, M., Scherer, S.,Stinchcomb, D. T., Struhl, K., and David, R. W. 1979. Sterile host yeast(SHY): a eukaryotic system of biological containment for recombinant DNAexperiments. Gene 8, 17-23

16 Gautvik, K. M., Teig, V., Halvorsen, J. F., Arnesen, E., Myhre, L.,Heimann, P., and Tollman, R. 1979. Development of sequence specificradioimmunoassay of human parathyroid hormone and its use in thediagnosis of hyperparathyroidism. Scand. J. clin. Lab. Invest. 39,469-478

17 Laemmli, U.K. 1970. Cleavage of structural proteins during assemblyof the head of bacteriophage T4. Nature 227, 680-685

18 Bdrk, R.R., Eschenbruch, M., Leuthard, P., and Steck, G. 1983.Sensitive Detection of Proteins and Peptides in Polyacrylamide Gelsafter Formaldehyde Fixation Methods in Enzymol. 91, 247-254

19 Towbin, H., Staehelin, T., and Gordon, J. 1979. Electrophoretictransfer of proteins from polyacrylamide gels to nitrocellulose sheets:Procedure and some applications. Proc. Natl. Acad. Sci. USA 76,4350-4354

20 Matsudaira, P. 1987. Sequence from Picomole Quantities of ProteinsElectroblotted onto Polyvinylidene Difluoride Membranes. J. Biol. Chem.262, 10035-10038

21 Gautvik, K. M., Gordeladze, J. O., Jahnsen, T., Haug, E., Hansson,V., and Lystad, E. 1983. Thyroliberin receptor binding and adenylylcyclase activation in cultured prolactin-producing rat pituitary tumorcells (GH cells). J. Biol. Chem. 258, 10304-10311

22 Gautvik, K. M., Gordeladze, J. O., Moxheim, E., and Gautvik, V. T.1984. Peripheral Metabolism of Parathyroid Hormone in Patients withPrimary Hyperparathyroidism as Judged by Immunological and BiologicalStudies. Eur. Surg. Res. 16 (suppl. 2), 41-54

23 Wingender, E., Bercz, G., Blocker, H., Frank, R., and Mayer, H. 1989.Expression of Human Parathyroid Hormone in Escherichia coli. J. Biol.Chem. 264, 4367-4373

24 Niall, H. D., Keutmann, H. T., Sauer, R., Hogan, M., Dawson, B.,Aurbach, G. D., and Potts, J. T. Jr. 1974. Hoppe Seylers Z. Physiol.Chem. 351, 1586

25 Sauer, R. T., Niall, H. D., Hogan, M. L., Keutmann, H. T., O'Riordan,J. L. H., and Potts, J. T. Jr. 1974. Biochemistry 13, 1994

26 Keutmann, H. T., Sauer, M. M., Hendy, G. N., O'Riordan, J. L. H., andPotts, J. T. Jr. 1978. Complete Amino Acid Sequence of Human ParathyroidHormone. Biochemistry 17, 5723-5729

27 Reeve, J., Meunier, P. J., Parsons, J. A., Bernat, M., Bijvoet, O. L.M., Courpron, P., Edouard, C., Klenerman, L., Neer, R. M., Renier, J.C., Slovik, D., Vismans, F. J. F. E., and Potts, J. T. Jr. 1980.Anabolic effect of human parathyroid hormone fragment on trabecular bonein involutional osteoporosis: a multicentre trial. Br. Med. J. 280,1340-1351

28 Slovik, D. M., Rosenthal, D. I., Doppelt, S. H., Potts, J. T. Jr.,Daly, M. A., Campbell, J. A., and Neer, R. M. 1986. Restoration ofSpinal Bone in Osteoporotic Men by Treatment With Human ParathyroidHormone (1-34) and 1,25-Dihydroxyvitamin D. J. Bone Min. Res. 1, 377-381

We claim:
 1. A process for producing recombinant parathyroid hormone(PTH) (1-84) protein comprising the steps of:(a) providing a yeastmicroorganism comprising:(1) a DNA sequence encoding the Saccharomycesmating factor α1 leader sequence as a leader sequence, said leadersequence lacking a STE13 recognition site; and (2) a DNA sequenceencoding PTH (1-84) protein, wherein the DNA encoding the leadersequence and the DNA sequence encoding PTH (1-84) protein are operablylinked; (b) culturing said yeast microorganism to allow expression ofsaid PTH (1-84) protein, thereby producing PTH (1-84), wherein the yeastmicroorganism cleaves the PTH (1-84) protein from the leader sequenceupon secretion of the PTH (1-84) protein from the yeast microorganism;and (c) purifying the resultant PTH (1-84) protein.
 2. The process ofclaim 1, wherein the PTH (1-84) is human PTH (1-84).
 3. The process ofclaim 2, wherein the microorganism comprises the plasmid pSSαUXPTH-ΔEA.4. The process of claim 3, wherein the yeast is Saccharomycescerevisiae.
 5. The process of claim 4, wherein the yeast isSaccharomyces cerevisiae strain BJ1991.
 6. The process of claim 1,wherein the protein has a purity of greater than 95%.
 7. A process forproducing recombinant parathyroid hormone (PTH) (1-84) proteincomprising the steps of:(a) providing a yeast microorganismcomprising:(1) a first DNA sequence encoding the first nineteen aminoacids of the Saccharomyces mating factor α1 as a leader sequence; and(2) a second DNA sequence encoding PTH (1-84) protein, wherein the DNAsequence encoding the leader sequence and the DNA sequence encoding PTH(1-84) protein are operably linked; (b) culturing said yeastmicroorganism to allow expression of said PTH (1-84) protein, therebyproducing PTH (1-84) protein, wherein the yeast microorganism cleavesthe PTH (1-84) protein from the leader sequence upon secretion of thePTH (1-84) protein from the yeast microorganism; and (c) purifying theresultant PTH (1-84) protein.
 8. The process of claim 7, wherein the PTHis human PTH.
 9. The process of claim 7, wherein the yeast isSaccharomyces cerevisiae.
 10. The process of claim 9, wherein the yeastis Saccharomyces cerevisiae strain BJ1991.
 11. The process of claim 7,wherein the protein has a purity of greater than 95%.
 12. A process forproducing recombinant parathyroid hormone (PTH) (1-84) proteincomprising the steps of:(a) providing a yeast microorganismcomprising:(1) a DNA encoding a leader sequence; and (2) a second DNAsequence encoding a peptide that is a derivative of PTH (1-84) protein,wherein the cleavage site after the pair of basic amino acids atpositions 25 and 26 of the derivative PTH (1-84) protein has beenmodified such that the hormone is excluded as a substrate for yscFprotease, wherein the DNA encoding the leader sequence and the DNAsequence encoding PTH (1-84) protein are operably linked; (b) culturingsaid yeast microorganism to allow expression of said PTH (1-84) proteinderivative, thereby producing PTH (1-84) protein, wherein the yeastmicroorganism cleaves the PTH (1-84) protein from the leader sequenceupon secretion of the PTH (1-84) protein from the yeast microorganism;and (c) purifying the resultant PTH (1-84) protein.
 13. The process ofclaim 12, wherein the PTH is human PTH.
 14. The process of claim 13,wherein amino acid 26 of the human PTH (1-84) protein is modified fromlysine to glutamine.
 15. The process of claim 12, wherein the leadersequence is the DNA sequence encoding Saccharomyces mating factor α1.16. The process of claim 15 comprising the expression plasmidpSSαUXPTH-ΔEA/KQ.
 17. The process of claim 12, wherein the yeast isSaccharomyces cerevisiae.
 18. The process of claim 17, wherein the yeastis Saccharomyces cerevisiae strain BJ1991.
 19. The process of claim 12,wherein the protein has a purity of greater than 95%.
 20. A process forproducing recombinant parathyroid hormone (PTH) (1-84) comprising thesteps of:(a) providing a yeast microorganism comprising:(1) a DNAsequence encoding PTH (1-84) protein; and (2) a second DNA sequenceencoding a signal sequence, wherein the signal sequence has thefollowing:(i) a positively charged amino-terminal; (ii) a hydrophobiccore region; and (iii) a polar COOH-terminal region, wherein the signalDNA sequence and the DNA sequence encoding PTH (1-84) protein areoperably linked; (b) culturing said yeast microorganism to allowexpression of said PTH (1-84) protein, thereby producing PTH (1-84)protein, wherein the yeast microorganism cleaves the PTH (1-84) proteinfrom the signal sequence upon secretion of the PTH (1-84) protein fromthe yeast microorganism; and (c) purifying the resultant PTH (1-84)protein.
 21. The process of claim 20, wherein the PTH is human PTH. 22.The process of claim 20, wherein the yeast is Saccharomyces cerevisiae.23. The process of claim 22, wherein the yeast is Saccharomycescerevisiae strain BJ1991.
 24. The process of claim 20, wherein thesignal sequence is a peptide selected from the consisting of: (1)Met-Lys-Ala-Lys-Leu-Leu-Val-Leu-Leu-Thr-Ala-Phe-Val-Ala-Thr-Asp-Ala; (2)Met-Arg-Ser-Leu-Leu-Ile-Leu-Val-Leu-Cys-Phe-Leu-Pro-Leu-Ala-Leu-Gly; and(3)Met-Arg-Phe-Ser-Ile-Phe-Thr-Ala-Val-Leu-Phe-Ala-Ala-Ser-Ser-Ala-Leu-Ala.25. The process of claim 20, wherein the protein has a purity of greaterthan 95%.
 26. A process for producing recombinant parathyroid hormone(PTH) (1-84) protein comprising the steps of:(a) providing a yeastmicroorganism comprising:(1) a DNA sequence encoding PTH (1-84) protein;and (2) a second DNA sequence encoding a functional signal sequencehaving the following sequenceMet-Asn-lie-Phe-Tyr-Ile-Phe-Leu-Phe-Leu-Ser-Phe-Val-Gln-Gly-Thr-Arg-Gly,and wherein the DNA encoding the signal sequence and the DNA sequenceencoding PTH (1-84) protein are operably linked; (b) culturing saidyeast microorganism to allow expression of said PTH (1-84) protein,thereby producing PTH (1-84) protein, wherein the yeast microorganismcleaves the PTH (1-84) protein from the signal sequence upon secretionof the PTH (1-84) protein from the yeast microorganism; and (c)purifying the resultant PTH (1-84) protein.
 27. The process of claim 26,wherein the PTH is human PTH.
 28. The process of claim 26, wherein theyeast is Saccharomyces cerevisiae.
 29. The process of claim 26, whereinthe yeast is Saccharomyces cerevisiae strain BJ1991.
 30. The process ofclaim 26, wherein the protein has a purity of greater than 95%.